CO2018005361A2 - Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración - Google Patents
Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duraciónInfo
- Publication number
- CO2018005361A2 CO2018005361A2 CONC2018/0005361A CO2018005361A CO2018005361A2 CO 2018005361 A2 CO2018005361 A2 CO 2018005361A2 CO 2018005361 A CO2018005361 A CO 2018005361A CO 2018005361 A2 CO2018005361 A2 CO 2018005361A2
- Authority
- CO
- Colombia
- Prior art keywords
- botulinum toxin
- methods
- long
- toxin formulations
- cosmetic effects
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/0059—Cosmetic or alloplastic implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/92—Oral administration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Psychology (AREA)
- Transplantation (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oral & Maxillofacial Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562248255P | 2015-10-29 | 2015-10-29 | |
PCT/US2016/059492 WO2017075468A1 (en) | 2015-10-29 | 2016-10-28 | Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2018005361A2 true CO2018005361A2 (es) | 2018-10-10 |
Family
ID=58630886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2018/0005361A CO2018005361A2 (es) | 2015-10-29 | 2018-05-23 | Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración |
Country Status (16)
Country | Link |
---|---|
US (2) | US20180311333A1 (de) |
EP (1) | EP3368071B1 (de) |
JP (2) | JP6955491B2 (de) |
KR (1) | KR20180077202A (de) |
CN (1) | CN109069608A (de) |
AU (2) | AU2016343748A1 (de) |
BR (1) | BR112018008684A2 (de) |
CA (1) | CA3003447A1 (de) |
CO (1) | CO2018005361A2 (de) |
DK (1) | DK3368071T3 (de) |
ES (1) | ES2907652T3 (de) |
IL (2) | IL259016A (de) |
MX (1) | MX2018005256A (de) |
RU (1) | RU2018119765A (de) |
SG (2) | SG11201803566TA (de) |
WO (1) | WO2017075468A1 (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2007136616A (ru) * | 2005-03-03 | 2009-04-10 | Риванс Терапьютикс, Инк. (Us) | Композиция и способ для местного применения и чрескожного введения ботулинового токсина |
MX366344B (es) | 2009-06-25 | 2019-07-05 | Revance Therapeutics Inc | Formulaciones de toxina botulinica libres de albumina. |
PT2490986T (pt) * | 2009-10-21 | 2018-11-13 | Revance Therapeutics Inc | Métodos e sistemas para purificar neurotoxina botulínica não complexada |
WO2017075468A1 (en) | 2015-10-29 | 2017-05-04 | Revance Therapeutics, Inc. | Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect |
JP2019535829A (ja) | 2016-11-21 | 2019-12-12 | エイリオン セラピューティクス, インコーポレイテッド | 大型薬剤の経皮送達 |
KR20190126894A (ko) * | 2017-03-22 | 2019-11-12 | 본티, 인크. | 치료법에서 사용하기 위한 보툴리눔 신경독소 |
EP3624819A4 (de) * | 2017-05-18 | 2021-03-24 | Revance Therapeutics, Inc. | Verfahren zur behandlung von zervikaler dystonie |
WO2018236873A1 (en) | 2017-06-19 | 2018-12-27 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIAL INFECTION |
EP3703738A4 (de) * | 2017-11-03 | 2021-09-08 | ReVance Therapeutics, Inc. | Botulinumtoxin-formulierungen und verfahren zu ihrer verwendung bei plantarem fersensporn mit verlängerter wirkungsdauer |
CN111655279A (zh) * | 2017-12-04 | 2020-09-11 | 雷文斯治疗公司 | 具有高应答率和长效应持续时间的可注射的肉毒杆菌毒素制剂及其使用方法 |
MX2021002993A (es) * | 2018-09-13 | 2021-08-11 | Allergan Inc | Métodos para el tratamiento de la hipertrofia del músculo masetero. |
SG11202110518XA (en) * | 2019-05-14 | 2021-10-28 | Eirion Therapeutics Inc | Delaying peak effect and/or extending duration of response |
BR112022018670A2 (pt) * | 2020-03-18 | 2022-11-01 | Revance Therapeutics Inc | Métodos de toxina botulínica injetável para tratar cefaleia |
KR102397708B1 (ko) * | 2020-04-29 | 2022-05-16 | 한국화학연구원 | 탄닌산을 포함하는 보툴리눔 독소 약제학적 조성물 |
KR102324855B1 (ko) * | 2020-05-20 | 2021-11-11 | 오스템임플란트 주식회사 | 보툴리눔 독소를 포함하는 약제학적 액상 조성물 |
KR102266384B1 (ko) * | 2021-01-25 | 2021-06-21 | 주식회사 울트라브이 | 필러용 생분해성 고분자 미세입자, 이를 포함한 필러용 동결건조체, 그 제조방법 및 상기 동결건조체를 포함하는 필러용 주사제 |
CN117561075A (zh) * | 2021-04-26 | 2024-02-13 | 上海科技大学 | 肉毒杆菌神经毒素的肌内注射组合物 |
WO2023239229A1 (ko) * | 2022-06-10 | 2023-12-14 | (주)메디톡스 | 보툴리눔 독소 안정화 조성물, 이를 포함하는 보툴리눔 독소 제제 및 이에 사용하기 위한 폴리펩티드 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5877278A (en) | 1992-09-24 | 1999-03-02 | Chiron Corporation | Synthesis of N-substituted oligomers |
US6444209B1 (en) | 1996-10-28 | 2002-09-03 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
EP1253932B1 (de) | 2000-02-08 | 2005-04-27 | Allergan, Inc. | Pharmazeutische zusammensetzungen mit botulinum toxin |
DE10043982A1 (de) * | 2000-09-05 | 2002-03-14 | Armin Maurer | Verfahren zur Verbesserung des Haarwuchses menschlichen Kopfhaares |
GB2416122A (en) | 2004-07-12 | 2006-01-18 | Ipsen Ltd | Botulinum neurotoxin composition |
CN102300584A (zh) | 2008-12-31 | 2011-12-28 | 雷文斯治疗公司 | 可注射的肉毒杆菌毒素制剂 |
MX366344B (es) | 2009-06-25 | 2019-07-05 | Revance Therapeutics Inc | Formulaciones de toxina botulinica libres de albumina. |
LT2661276T (lt) * | 2011-01-07 | 2017-12-11 | Revance Therapeutics, Inc. | Paviršinio naudojimo kompozicija, apimanti botulino toksiną ir dažą |
CN104602703A (zh) * | 2012-03-22 | 2015-05-06 | 雷文斯治疗公司 | 使用局部化学性去神经支配剂处理皱纹的方法 |
CA2889833A1 (en) * | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions and methods for safe treatment of rhinitis |
WO2017075468A1 (en) | 2015-10-29 | 2017-05-04 | Revance Therapeutics, Inc. | Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect |
-
2016
- 2016-10-28 WO PCT/US2016/059492 patent/WO2017075468A1/en active Application Filing
- 2016-10-28 US US15/771,635 patent/US20180311333A1/en not_active Abandoned
- 2016-10-28 SG SG11201803566TA patent/SG11201803566TA/en unknown
- 2016-10-28 BR BR112018008684A patent/BR112018008684A2/pt active Search and Examination
- 2016-10-28 RU RU2018119765A patent/RU2018119765A/ru not_active Application Discontinuation
- 2016-10-28 JP JP2018522570A patent/JP6955491B2/ja active Active
- 2016-10-28 CN CN201680072956.XA patent/CN109069608A/zh active Pending
- 2016-10-28 DK DK16860952.7T patent/DK3368071T3/da active
- 2016-10-28 SG SG10202004337WA patent/SG10202004337WA/en unknown
- 2016-10-28 EP EP16860952.7A patent/EP3368071B1/de active Active
- 2016-10-28 KR KR1020187014681A patent/KR20180077202A/ko not_active Application Discontinuation
- 2016-10-28 CA CA3003447A patent/CA3003447A1/en active Pending
- 2016-10-28 AU AU2016343748A patent/AU2016343748A1/en not_active Abandoned
- 2016-10-28 MX MX2018005256A patent/MX2018005256A/es unknown
- 2016-10-28 ES ES16860952T patent/ES2907652T3/es active Active
-
2018
- 2018-04-29 IL IL259016A patent/IL259016A/en unknown
- 2018-05-23 CO CONC2018/0005361A patent/CO2018005361A2/es unknown
-
2021
- 2021-09-10 US US17/472,525 patent/US20220062400A1/en active Pending
- 2021-09-19 IL IL286472A patent/IL286472A/en unknown
- 2021-10-01 JP JP2021162802A patent/JP2022008814A/ja active Pending
-
2023
- 2023-10-06 AU AU2023241373A patent/AU2023241373A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2018005256A (es) | 2019-09-04 |
EP3368071B1 (de) | 2022-01-26 |
BR112018008684A2 (pt) | 2018-11-27 |
RU2018119765A3 (de) | 2020-03-17 |
RU2018119765A (ru) | 2019-12-02 |
AU2016343748A1 (en) | 2018-05-17 |
IL286472A (en) | 2021-10-31 |
EP3368071A1 (de) | 2018-09-05 |
US20220062400A1 (en) | 2022-03-03 |
CA3003447A1 (en) | 2017-05-04 |
KR20180077202A (ko) | 2018-07-06 |
SG11201803566TA (en) | 2018-05-30 |
SG10202004337WA (en) | 2020-06-29 |
JP2018531984A (ja) | 2018-11-01 |
CN109069608A (zh) | 2018-12-21 |
US20180311333A1 (en) | 2018-11-01 |
IL259016A (en) | 2018-06-28 |
DK3368071T3 (da) | 2022-05-02 |
JP2022008814A (ja) | 2022-01-14 |
WO2017075468A1 (en) | 2017-05-04 |
ES2907652T3 (es) | 2022-04-25 |
JP6955491B2 (ja) | 2021-10-27 |
AU2023241373A1 (en) | 2023-10-26 |
EP3368071A4 (de) | 2019-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018005361A2 (es) | Formulaciones inyectables de toxina botulínica y sus métodos de uso que poseen efecto terapéutico o cosmético de larga duración | |
CL2020000501A1 (es) | Inhibidores de la ectonucleótido pirofosfatasa-fosfodiesterasa 1 (enpp1) y usos de los mismos. | |
ECSP19010079A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
CL2019002255A1 (es) | 2-heteroaril-3-oxo-2,3-dihidropiridazin-4-carboxamidas. | |
CR20190318A (es) | Compuestos heterocíclicos como inmunomoduladores | |
BR112017018368A2 (pt) | composições contendo rna para o tratamento de doenças tumorais | |
DOP2017000261A (es) | Derivados de ciclohexano sustituido con amido | |
CO2020008231A2 (es) | Formulaciones inyectables de toxina botulínica y métodos de uso de las mismas que tienen una alta tasa de respuesta y una larga duración del efecto | |
BR112015018270A2 (pt) | composições que compreendem 15-ohepa e métodos de uso das mesmas | |
SV2017005466A (es) | Pirazolpiridinaminas como inhibidores de mknk1 y mknk2 | |
CO2020005919A2 (es) | Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas | |
AR101236A1 (es) | Composiciones para el cuidado oral | |
DOP2016000170A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
CR20150653A (es) | Compuestos nuevos para el tratamiento del cáncer | |
UY35651A (es) | Pirazolpiridinas sustituidas | |
DOP2020000100A (es) | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3 | |
GT201700126A (es) | Ácidos piridil-cicloalquil-carboxílicos sustituidos composiciones que los contienen y usos de los mismos | |
ECSP20020949A (es) | Conjugados de fármaco-anticuerpo (adc) anti-egfr y sus usos | |
CL2020002519A1 (es) | Composiciones de erenumab y usos de las mismas | |
BR112019017314A2 (pt) | composições farmacêuticas para terapia de combinação | |
CL2018002848A1 (es) | Formulaciones liquidas de fosfoplatino | |
ECSP22021881A (es) | Composición farmacéutica acuosa de anticuerpo anti-pd1 prolgolimab y su uso | |
CR20150641U (es) | Composiciones farmacéuticas | |
UY36983A (es) | Pirazolopiridinaminas sustituidas | |
AR099681A1 (es) | Composiciones de grapiprant y métodos para su utilización |